Needham analyst Alan Carr maintained a Buy rating on SCYNEXIS (SCYX) today and set a price target of $5. The company’s shares opened today at $1.50.
“Scynexis reported 4Q18 financial results and we spoke w/ mgmt for an update. Two ibrexafungerp Candidiasis (VVC) trials are underway. A third Phase 3 trial in recurrent VVC is expected to begin enrolling pts in 2Q19. Results from the acute VVC trials are expected in 1H20, followed by recurrent VVC in 1H21. Based on in vitro and clinical data, we expect a positive outcome for the Phase 3 program. We believe the commercial opportunity is substantially underappreciated. Given that only one oral agent is currently available (fluconazole), ObGyn interest in a new oral agent is high. FURI and CARES trial data are expected at upcoming ECCMID mtg. These trials are evaluating oral ibrexafungerp in pts w/ challenging infections, including C. auris. BUY.”
According to TipRanks.com, Carr is a 4-star analyst with an average return of 3.9% and a 44.4% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Lexicon Pharmaceuticals.
SCYNEXIS has an analyst consensus of Strong Buy, with a price target consensus of $6.33.
See today’s analyst top recommended stocks >>
Based on SCYNEXIS’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $351K. In comparison, last year the company had a GAAP net loss of $7.59 million.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SCYX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SCYNEXIS, Inc. engages in the development and commercialization of novel anti-infectives, which addresses the significant unmet therapeutic needs. It develops a novel oral and intravenous drug for several fungal infections, including serious and life-threatening invasive fungal infections.